Q32 Bio (NASDAQ:QTTB) CFO Lee Kalowski Sells 1,301 Shares of Stock

Posted by George Bondi on Oct 15th, 2026

Q32 Bio Inc. (NASDAQ:QTTB – Get Free Report) CFO Lee Kalowski sold 1,301 shares of the company’s stock in a transaction dated Tuesday, October 6th. The stock was sold at an average price of $8.32, for a total transaction of $10,824.32. Following the completion of the sale, the chief financial officer owned 137,170 shares in the company, valued at approximately $1,141,254.40. This trade represents a 0.94% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Lee Kalowski also recently made the following trade(s):

On Tuesday, August 25th, Lee Kalowski sold 3,972 shares of Q32 Bio stock. The shares were sold at an average price of $16.56, for a total transaction of $65,776.32.

Q32 Bio Stock Performance

QTTB stock opened at $8.01 on Thursday. The firm has a 50 day moving average price of $12.08 and a 200-day moving average price of $10.88. Q32 Bio Inc. has a 52-week low of $1.90 and a 52-week high of $23.57. The firm has a market capitalization of $238.46 million, a price-to-earnings ratio of 3.89 and a beta of 0.31.

Q32 Bio (NASDAQ:QTTB – Get Free Report) last issued its quarterly earnings results on Wednesday, August 5th. The company reported ($0.44) EPS for the quarter, topping analysts’ consensus estimates of ($0.46) by $0.02. As a group, sell-side analysts forecast that Q32 Bio Inc. will post -1.54 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently commented on QTTB shares. Morgan Stanley assumed coverage on Q32 Bio in a research note on Monday, August 24th. They issued an “overweight” rating and a $34.00 target price on the stock. Weiss Ratings upgraded shares of Q32 Bio from a “hold (c-)” rating to a “hold (c)” rating in a research note on Friday, August 21st. Mizuho upgraded shares of Q32 Bio to a “strong-buy” rating in a research note on Monday, September 7th. Leerink Partners initiated coverage on shares of Q32 Bio in a research report on Monday. They set an “outperform” rating and a $40.00 price objective on the stock. Finally, Oppenheimer restated an “outperform” rating on shares of Q32 Bio in a research note on Thursday, October 1st. One analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and two have issued a Hold rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $32.17.

Get Our Latest Report on Q32 Bio

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of QTTB. Atlas Venture Life Science Advisors LLC grew its position in Q32 Bio by 29.9% during the second quarter. Atlas Venture Life Science Advisors LLC now owns 2,717,106 shares of the company’s stock valued at $34,616,000 after buying an additional 625,000 shares during the period. BlackRock Inc. purchased a new stake in Q32 Bio during the second quarter valued at approximately $1,510,000. Renaissance Technologies LLC raised its position in Q32 Bio by 107.7% in the first quarter. Renaissance Technologies LLC now owns 206,915 shares of the company’s stock worth $1,328,000 after acquiring an additional 107,315 shares during the period. Carlyle Group Inc. bought a new position in Q32 Bio in the second quarter worth approximately $769,000. Finally, Squarepoint Ops LLC bought a new position in Q32 Bio in the second quarter worth approximately $303,000. 31.32% of the stock is owned by hedge funds and other institutional investors.

Q32 Bio Company Profile

(Get Free Report)

Q32 Bio is a clinical-stage biotechnology company focused on developing therapies designed to restore immune homeostasis and address diseases driven by immune dysregulation. The company’s approach targets pathways involved in the transforming growth factor beta superfamily, which plays a role in regulating inflammation, tissue repair and immune responses.

Q32 Bio’s lead product candidate is bempikibart, also known as ADX-914, a fully human monoclonal antibody designed to modulate immune activity through selective targeting of the activin receptor type IIA pathway.